molybdenum has been researched along with Hepatolenticular Degeneration in 83 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 9 (10.84) | 18.7374 |
1990's | 23 (27.71) | 18.2507 |
2000's | 31 (37.35) | 29.6817 |
2010's | 18 (21.69) | 24.3611 |
2020's | 2 (2.41) | 2.80 |
Authors | Studies |
---|---|
Auger, C; Cardona, I; De Fabregues, O; Palasí, A; Quintana, M; Vargas, V; Viñas, J | 1 |
Aggarwal, A; Bhatt, M | 1 |
Członkowska, A; Litwin, T | 1 |
Rupp, C; Stremmel, W; Weiss, KH | 1 |
Houwen, R | 1 |
Pfister, ED | 1 |
Boyling, L; Plitz, T | 1 |
Członkowska, A; Ferenci, P; Hedera, P; Weiss, KH | 1 |
Stremmel, W | 1 |
Członkowska, A; Dusek, P; Ferenci, P; Litwin, T; Lutsenko, S; Medici, V; Rybakowski, JK; Schilsky, ML; Weiss, KH | 1 |
Appenzeller-Herzog, C; Ewald, H; Heeres, MLS; Houwen, RHJ; Mathes, T; Weiss, KH | 1 |
Purchase, R | 1 |
Brůha, R; Mareček, Z | 1 |
Stremmel, W; Weiss, KH | 1 |
Chen, DB; Feng, L; Hou, HM; Li, XH; Liu, JX; Wei, LT; Wu, C; Zhang, JW | 1 |
Chen, C; Li, WJ; Wang, XP; Yang, RM; You, ZF | 1 |
Buszewski, B; Jurowska, A; Jurowski, K; Kalenik, T; Piekoszewski, W; Szklarzewicz, J | 1 |
Brewer, GJ | 6 |
George, GN; Lichtmannegger, J; Pickering, IJ; Summer, KH; Webb, S; Zhang, L | 1 |
Brewer, GJ; Dick, R; Hou, G | 1 |
Khan, G; Merajver, S | 1 |
Gilman, S; Pestana Knight, EM; Selwa, L | 1 |
Askari, F; Brewer, GJ; Carlson, M; Dick, RB; Fink, JK; Kluin, KJ; Lorincz, MT; Sitterly, J | 1 |
Anan, Y; Miyayama, T; Ogra, Y | 1 |
Askari, F; Brewer, GJ; Burke, JF; Dayalu, P; Lorincz, MT; Nan, B | 1 |
Suttle, NF | 1 |
Pérez-Aguilar, F | 1 |
Gailer, J; George, GN; Harris, HH; Klein, D; Lichtmannegger, J; Pickering, IJ; Summer, KH | 1 |
Askari, F; Brewer, GJ; Carlson, M; Dick, RB; Fink, JK; Hedera, P; Kluin, KJ; Sitterly, J | 1 |
Brechbiel, M; Camphausen, K; Sproull, M | 1 |
El-Youssef, M | 1 |
Al-Mateen, M; Brewer, GJ; Carlson, MD | 1 |
Szalay, F | 1 |
Arora, U; Finckh, M; Heinzmann, U; Klein, D; Lichtmannegger, J; Summer, KH | 1 |
Hayashi, H; Suzuki, R; Wakusawa, S | 1 |
Crone, NE; Jinnah, HA; Reich, SG | 1 |
Algayres, JP; Amezyane, T; Béchade, D; Coutant, G; Desramé, J; Le Berre, JP; Lecoules, S | 1 |
Askari, F; Brewer, GJ; Carlson, M; Dick, RB; Fink, JK; Hedera, P; Kluin, KJ; Lorincz, MT; Moretti, P; Schilsky, M; Sitterly, J; Tankanow, R | 1 |
Bigotto, MA; D'Incà, R; Dal Pont, E; Martines, D; Medici, V; Sturniolo, GC; Trevisan, CP | 1 |
Medici, V; Rossaro, L; Sturniolo, GC | 1 |
Scheinberg, IH; Sternlieb, I | 1 |
Aisen, A; Brewer, GJ; Dick, RD; Fink, JK; Johnson, V; Kluin, K; Wang, Y; Yuzbasiyan-Gurkan, V | 1 |
Ogra, Y; Ohmichi, M; Suzuki, KT | 3 |
Schilsky, ML | 2 |
Brewer, GJ; Brunberg, JA; Dick, RD; Fink, JK; Johnson, V; Kluin, KJ | 1 |
Brewer, GJ; Burnstine, MA; Esmaeli, B; Johnson, V; Martonyi, CL; Sugar, A | 1 |
Lyndon, B; Walter, G | 1 |
Grigg, A; Karunajeewa, H; Metz, J; Wall, A | 1 |
Aoki, T | 1 |
Ogra, Y; Suzuki, KT | 1 |
Ikeda, T; Lai, YR; Sugawara, C; Sugawara, N | 1 |
Lai, YR; Sugawara, C; Sugawara, N | 1 |
Komada, Y; Ogra, Y; Suzuki, KT | 1 |
Chikusa, H; Ogra, Y; Suzuki, KT | 1 |
Ogura, Y; Suzuki, KT | 1 |
Cherian, MG; Czachor, JD; Koropatnick, J | 1 |
Brewer, GJ; Cohen, EJ; Laibson, PR; Liu, M | 1 |
Bronstein, JM; Subramanian, I; Vanek, ZF | 1 |
Reinhold, JG | 1 |
Cramarossa, L; D'Angelo, D; D'Ascanio, I; Ferri, GB; Piane, E | 1 |
Lamand, M; Mason, J; McQuaid, A | 1 |
Walshe, JM | 1 |
Brewer, GJ; Dick, RD; Kluin, KJ; Tankanow, R; Young, AB; Yuzbasiyan-Gurkin, V | 1 |
Mason, J; McQuaid, A | 1 |
Danks, DM | 2 |
Bartsch, R; Klein, D; Summer, KH | 1 |
Mason, J; McQuaid, A; Pheiffer, H | 1 |
Brewer, GJ; Yuzbasiyan-Gurkan, V | 1 |
Mason, J | 1 |
Harper, PL; Walshe, JM | 1 |
Seelig, MS | 1 |
Oberleas, D; Prasad, AS; Rajasekaran, G | 1 |
Loĭko, EA | 1 |
38 review(s) available for molybdenum and Hepatolenticular Degeneration
Article | Year |
---|---|
Wilson disease.
Topics: Clinical Trials as Topic; Copper; Copper-Transporting ATPases; Hepatolenticular Degeneration; Humans; Molybdenum; Phenotype | 2020 |
Wilson disease - currently used anticopper therapy.
Topics: Chelating Agents; Copper; Enzyme Inhibitors; Hepatolenticular Degeneration; Humans; Molybdenum; Penicillamine; Prospective Studies; Trientine | 2017 |
Novel perspectives on Wilson disease treatment.
Topics: Animals; Chelating Agents; Copper; Genetic Therapy; Hepatolenticular Degeneration; Humans; Molybdenum | 2017 |
[Wilson's disease : What has been confirmed in diagnostic and therapy?]
Topics: Chelating Agents; Chromosome Aberrations; Copper; Diet Therapy; Genes, Recessive; Hepatolenticular Degeneration; Humans; Liver Transplantation; Molybdenum; Penicillamine; Phenotype; Zinc | 2017 |
WTX101 - an investigational drug for the treatment of Wilson disease.
Topics: Administration, Oral; Animals; Chelating Agents; Copper; Drug Design; Drugs, Investigational; Hepatolenticular Degeneration; Humans; Molybdenum | 2018 |
Wilson disease.
Topics: Chelating Agents; Copper; Dietary Supplements; Hepatolenticular Degeneration; Humans; Molybdenum; Quality of Life | 2018 |
Comparative effectiveness of common therapies for Wilson disease: A systematic review and meta-analysis of controlled studies.
Topics: Chelating Agents; Copper; Hepatolenticular Degeneration; Humans; Liver; Molybdenum; Penicillamine; Randomized Controlled Trials as Topic; Trientine; Zinc | 2019 |
The treatment of Wilson's disease, a rare genetic disorder of copper metabolism.
Topics: Brain; Chelating Agents; Copper; Cornea; Dimercaprol; Drug Discovery; Hepatolenticular Degeneration; History, 20th Century; Humans; Liver; Molybdenum; Penicillamine; Rare Diseases; Trientine; Zinc Sulfate | 2013 |
[Wilsons disease].
Topics: Adenosine Triphosphatases; Adult; Cation Transport Proteins; Chelating Agents; Copper; Copper-Transporting ATPases; Czech Republic; Female; Hepatolenticular Degeneration; Humans; Liver Cirrhosis; Liver Transplantation; Male; Molybdenum; Mutation; Penicillamine; Trientine; Zinc | 2013 |
Clinical considerations for an effective medical therapy in Wilson's disease.
Topics: Ceruloplasmin; Chelating Agents; Copper; Hepatolenticular Degeneration; Humans; Molybdenum; Penicillamine; Trientine; Zinc | 2014 |
Current Drug Managements of Wilson's Disease: From West to East.
Topics: Chelating Agents; Copper; Hepatolenticular Degeneration; Humans; Medicine, Chinese Traditional; Molybdenum; Penicillamine; Succimer; Treatment Outcome; Trientine; Zinc | 2016 |
Molybdenum Metallopharmaceuticals Candidate Compounds - The "Renaissance" of Molybdenum Metallodrugs?
Topics: Animals; Atherosclerosis; Cell Cycle Checkpoints; Coordination Complexes; Hepatolenticular Degeneration; Humans; Huntington Disease; Molybdenum; Tungsten Compounds | 2016 |
The risks of free copper in the body and the development of useful anticopper drugs.
Topics: Alzheimer Disease; Angiogenesis Inhibitors; Autoimmunity; Copper; Fibrosis; Hepatolenticular Degeneration; Humans; Inflammation; Molybdenum; Neurodegenerative Diseases; Penicillamine; Trientine | 2008 |
Copper chelation in cancer therapy using tetrathiomolybdate: an evolving paradigm.
Topics: Animals; Antineoplastic Agents; Chelating Agents; Copper; Hepatolenticular Degeneration; Humans; Molybdenum; Neoplasms | 2009 |
Zinc and tetrathiomolybdate for the treatment of Wilson's disease and the potential efficacy of anticopper therapy in a wide variety of diseases.
Topics: Chelating Agents; Copper; Hepatolenticular Degeneration; Humans; Molybdenum; Zinc | 2009 |
Copper imbalances in ruminants and humans: unexpected common ground.
Topics: Alzheimer Disease; Animals; Chelating Agents; Copper; Deficiency Diseases; Enzyme Inhibitors; Hepatolenticular Degeneration; Humans; Infections; Inflammation; Molybdenum; Neoplasms; Nutritional Requirements; Ruminants | 2012 |
[Wilson's disease: physiopathological, clinical and therapeutic considerations].
Topics: Adenosine Triphosphatases; Adolescent; Adult; Basal Ganglia Diseases; Brain; Cation Transport Proteins; Ceruloplasmin; Chelating Agents; Chelation Therapy; Copper; Copper-Transporting ATPases; Descemet Membrane; Female; Genes, Recessive; Hepatitis, Chronic; Hepatolenticular Degeneration; Humans; Liver Transplantation; Male; Mental Disorders; Middle Aged; Molybdenum; Penicillamine; Pregnancy; Pregnancy Complications; Prognosis; Recombinant Fusion Proteins; Trientine; Zinc | 2003 |
Antiangiogenic therapy through copper chelation.
Topics: Angiogenesis Inhibitors; Animals; Chelating Agents; Chelation Therapy; Copper; Corneal Neovascularization; Cyclohexylamines; Hepatolenticular Degeneration; Humans; Molybdenum; Neoplasms; Neovascularization, Pathologic; Penicillamine; Pyridines; Rabbits; Trientine | 2003 |
Wilson disease.
Topics: Adenosine Triphosphatases; Chelating Agents; Copper; Hepatolenticular Degeneration; Humans; Liver Transplantation; Molybdenum; Penicillamine; Trientine; Zinc | 2003 |
[Wilson disease in 2003].
Topics: Adenosine Triphosphatases; Cation Transport Proteins; Chelating Agents; Copper; Copper-Transporting ATPases; Diagnosis, Differential; Family Planning Services; Genetic Counseling; Genotype; Hepatolenticular Degeneration; Humans; Molybdenum; Penicillamine; Phenotype; Trientine; Zinc Acetate; Zinc Sulfate | 2003 |
[Wilson's disease and its pharmacological treatment].
Topics: Adenosine Triphosphatases; Biomarkers; Cation Transport Proteins; Ceruloplasmin; Chelating Agents; Chelation Therapy; Copper; Copper-Transporting ATPases; Female; Hepatolenticular Degeneration; Humans; Iron; Male; Molecular Diagnostic Techniques; Molybdenum; Mutation; Penicillamine; Pregnancy; Pregnancy Outcome; Zinc Acetate | 2004 |
Neurologically presenting Wilson's disease: epidemiology, pathophysiology and treatment.
Topics: Behavior; Chelating Agents; Enzyme Inhibitors; Hepatolenticular Degeneration; Humans; Molybdenum; Nervous System Diseases; Penicillamine; Trientine; Zinc | 2005 |
Novel therapeutic approaches to the treatment of Wilson's disease.
Topics: Chelating Agents; Child; Child, Preschool; Clinical Trials as Topic; Copper; Female; Hepatolenticular Degeneration; Humans; Molybdenum; Penicillamine; Pregnancy; Pregnancy Complications; Zinc | 2006 |
Wilson disease--a practical approach to diagnosis, treatment and follow-up.
Topics: Ceruloplasmin; Chelating Agents; Copper; Hepatolenticular Degeneration; Humans; Liver Transplantation; Molybdenum; Mutation; Penicillamine; Trace Elements; Treatment Outcome; Trientine; Zinc | 2007 |
Practical recommendations and new therapies for Wilson's disease.
Topics: Chelating Agents; Copper; Female; Hepatolenticular Degeneration; Humans; Liver; Metallothionein; Molybdenum; Penicillamine; Pregnancy; Trientine; Zinc | 1995 |
Wilson disease: genetic basis of copper toxicity and natural history.
Topics: Adenosine Triphosphatases; Carrier Proteins; Cation Transport Proteins; Chelating Agents; Chelation Therapy; Chromosome Mapping; Copper; Copper-Transporting ATPases; Environment; Genetic Therapy; Genome, Human; Hepatitis; Hepatolenticular Degeneration; Humans; Liver Transplantation; Molybdenum; Mutation; Penicillamine; Risk Factors; Trientine; Zinc | 1996 |
[Inborn errors of trace metals].
Topics: Copper; Hemochromatosis; Hepatolenticular Degeneration; Humans; Iron; Menkes Kinky Hair Syndrome; Metal Metabolism, Inborn Errors; Molybdenum; Zinc | 1998 |
[Biological regulation of copper and selective removal of copper: therapy for Wilson disease and its molecular mechanism].
Topics: Adenosine Triphosphatases; Animals; Carrier Proteins; Cation Transport Proteins; Chelating Agents; Copper; Copper-Transporting ATPases; Disease Models, Animal; Hepatolenticular Degeneration; Humans; Liver; Metallothionein; Molybdenum; Rats; Rats, Inbred LEC; Recombinant Fusion Proteins | 2000 |
Treatment of Wilson's disease: what are the relative roles of penicillamine, trientine, and zinc supplementation?
Topics: Adenosine Triphosphatases; Chelating Agents; Drug Therapy, Combination; Female; Hepatolenticular Degeneration; Humans; Molybdenum; Penicillamine; Pregnancy; Trientine; Zinc | 2001 |
Copper control as an antiangiogenic anticancer therapy: lessons from treating Wilson's disease.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Copper; Hepatolenticular Degeneration; Humans; Molybdenum; Neoplasms; Zinc | 2001 |
Diagnosis and treatment of Wilson's disease.
Topics: Chelating Agents; Copper; Dimercaprol; Enzyme Inhibitors; Female; Hepatolenticular Degeneration; Humans; Liver Transplantation; Male; Molybdenum; Penicillamine; Trientine; Zinc | 2002 |
Trace elements--a selective survey.
Topics: Adult; Child; Chromium; Cobalt; Copper; Erythrocytes; Fluorine; Hepatolenticular Degeneration; Humans; Iodine; Iron; Magnesium; Microchemistry; Molybdenum; Nickel; Nutritional Physiological Phenomena; Protein Binding; Selenium; Silicon; Tin; Trace Elements; Vanadium; Zinc | 1975 |
[Wilson's disease].
Topics: Acetates; Acetic Acid; Adult; Diagnosis, Differential; Diet; Female; Hepatolenticular Degeneration; Humans; Male; Molybdenum; Penicillamine; Pyridoxine; Sulfates; Trientine; Zinc; Zinc Sulfate | 1992 |
Copper and liver disease.
Topics: Adult; Chelating Agents; Child; Cholestasis; Copper; Hepatolenticular Degeneration; Humans; Infant; Infant, Newborn; Liver Diseases; Molybdenum; Penicillamine; Zinc | 1991 |
Wilson's disease: an update, with emphasis on new approaches to treatment.
Topics: Copper; Female; Hepatolenticular Degeneration; Humans; Molybdenum; Penicillamine; Pregnancy; Trientine; Zinc | 1989 |
Thiomolybdates: mediators of molybdenum toxicity and enzyme inhibitors.
Topics: Animals; Copper; Enzyme Inhibitors; Hepatolenticular Degeneration; Humans; Liver; Molybdenum | 1986 |
Inborn errors of trace element metabolism.
Topics: Acrodermatitis; Animals; Breast Feeding; Copper; Cutis Laxa; Disease Models, Animal; Female; Hepatolenticular Degeneration; Humans; Infant, Newborn; Infant, Premature, Diseases; Liver; Manganese; Menkes Kinky Hair Syndrome; Metabolism, Inborn Errors; Molybdenum; Pregnancy; Prenatal Diagnosis; Trace Elements; Zinc | 1985 |
Proposed role of copper-molybdenum interaction in iron-deficiency and iron -storage diseases.
Topics: Adult; Anemia; Anemia, Hemolytic; Anemia, Hypochromic; Anemia, Sickle Cell; Animals; Copper; Deficiency Diseases; Female; Hemoglobins; Hepatolenticular Degeneration; Humans; Infant; Infant Nutrition Disorders; Infant, Newborn; Infant, Premature, Diseases; Iron; Liver; Metabolic Diseases; Molybdenum; Pregnancy; Pregnancy Complications, Hematologic | 1973 |
3 trial(s) available for molybdenum and Hepatolenticular Degeneration
Article | Year |
---|---|
Treatment of Wilson disease with ammonium tetrathiomolybdate: III. Initial therapy in a total of 55 neurologically affected patients and follow-up with zinc therapy.
Topics: Adult; Child; Enzyme Inhibitors; Female; Follow-Up Studies; Hepatolenticular Degeneration; Humans; Male; Molybdenum; Nervous System Diseases; Neurologic Examination; Treatment Outcome; Zinc | 2003 |
Treatment of Wilson disease with ammonium tetrathiomolybdate: IV. Comparison of tetrathiomolybdate and trientine in a double-blind study of treatment of the neurologic presentation of Wilson disease.
Topics: Adolescent; Adult; Anemia; Chelating Agents; Copper; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Hepatolenticular Degeneration; Humans; Length of Stay; Male; Middle Aged; Molybdenum; Serum Albumin; Speech; Speech Disorders; Treatment Outcome; Trientine; Zinc | 2006 |
Treatment of Wilson disease with ammonium tetrathiomolybdate. II. Initial therapy in 33 neurologically affected patients and follow-up with zinc therapy.
Topics: Adolescent; Adult; Female; Follow-Up Studies; Hepatolenticular Degeneration; Humans; Liver; Male; Molybdenum; Nervous System; Neurologic Examination; Speech-Language Pathology; Time Factors; Treatment Outcome; Zinc | 1996 |
42 other study(ies) available for molybdenum and Hepatolenticular Degeneration
Article | Year |
---|---|
Ammonium tetrathiomolybdate in the decoppering phase treatment of Wilson's disease with neurological symptoms: A case series.
Topics: Brain; Hepatolenticular Degeneration; Humans; Longitudinal Studies; Magnetic Resonance Imaging; Molybdenum | 2020 |
Bis-choline tetrathiomolybdate for Wilson's disease.
Topics: Choline; Copper; Hepatolenticular Degeneration; Humans; Molybdenum | 2017 |
Metabolic disposition of WTX101 (bis-choline tetrathiomolybdate) in a rat model of Wilson disease.
Topics: Animals; Bile; Biological Transport; Chelating Agents; Copper; Feces; Hepatolenticular Degeneration; Molybdenum; Rats; Urine | 2019 |
Bis-choline Tetrathiomolybdate as Old Drug in a New Design for Wilson's Disease: Good for Brain and Liver?
Topics: Brain; Choline; Hepatolenticular Degeneration; Humans; Liver; Molybdenum | 2019 |
Effects of tetrathiomolybdate and penicillamine on brain hydroxyl radical and free copper levels: a microdialysis study in vivo.
Topics: Animals; Brain; Chelating Agents; Copper; Corpus Striatum; Disease Models, Animal; Hepatolenticular Degeneration; Hydroxyl Radical; Mice, Inbred C57BL; Mice, Mutant Strains; Microdialysis; Molybdenum; Penicillamine | 2015 |
Tracing copper-thiomolybdate complexes in a prospective treatment for Wilson's disease.
Topics: Adenosine Triphosphatases; Animals; Cation Transport Proteins; Chelating Agents; Copper; Copper-Transporting ATPases; Disease Models, Animal; Hepatolenticular Degeneration; Kidney; Liver; Molybdenum; Prospective Studies; Rats; Rats, Inbred LEC; Rats, Mutant Strains | 2009 |
Improvement in dissolution of liver fibrosis in an animal model by tetrathiomolybdate.
Topics: Animals; Carbon Tetrachloride; Carbon Tetrachloride Poisoning; Copper; Female; Hepatolenticular Degeneration; Humans; Liver Cirrhosis, Experimental; Mice; Mice, Inbred BALB C; Molybdenum; Time Factors | 2009 |
Status epilepticus in Wilson's disease.
Topics: Brain; Chelating Agents; Electroencephalography; Functional Laterality; Hepatolenticular Degeneration; Humans; Liver Cirrhosis; Magnetic Resonance Imaging; Male; Middle Aged; Molybdenum; Review Literature as Topic; Seizures; Status Epilepticus; Treatment Outcome | 2009 |
Treatment of Wilson's disease with tetrathiomolybdate: V. Control of free copper by tetrathiomolybdate and a comparison with trientine.
Topics: Chelating Agents; Clinical Trials as Topic; Copper; Double-Blind Method; Drug Administration Schedule; Hepatolenticular Degeneration; Humans; Molybdenum; Retrospective Studies; Trientine | 2009 |
Effect of glutathione depletion on removal of copper from LEC rat livers by tetrathiomolybdate.
Topics: Animals; Buthionine Sulfoximine; Chelating Agents; Copper; Enzyme Inhibitors; Glutathione; Hepatolenticular Degeneration; Humans; Liver; Male; Metallothionein; Molybdenum; Oxidation-Reduction; Rats; Rats, Inbred LEC; Rats, Wistar; Time Factors | 2010 |
Prognostic significance of neurologic examination findings in Wilson disease.
Topics: Adult; Chelating Agents; Dystonia; Female; Hepatolenticular Degeneration; Humans; Male; Molybdenum; Neurologic Examination; Prognosis; Risk Factors; Tremor; Trientine; Zinc | 2011 |
Tetrathiomolybdate causes formation of hepatic copper-molybdenum clusters in an animal model of Wilson's disease.
Topics: Animals; Copper; Disease Models, Animal; Fourier Analysis; Hepatolenticular Degeneration; Humans; Liver; Lysosomes; Molecular Structure; Molybdenum; Rats; Rats, Inbred LEC; Spectrometry, X-Ray Emission; Sulfur | 2003 |
Atypical childhood Wilson's disease.
Topics: Child; Diagnosis, Differential; Female; Hepatolenticular Degeneration; Humans; Molybdenum | 2004 |
Tetrathiomolybdate in the treatment of acute hepatitis in an animal model for Wilson disease.
Topics: Acute Disease; Animals; Chelating Agents; Copper; Disease Models, Animal; Female; Hepatitis, Animal; Hepatolenticular Degeneration; Liver; Microscopy, Electron; Molybdenum; Rats; Rats, Inbred LEC; Rats, Long-Evans; Subcellular Fractions; Tissue Distribution | 2004 |
Wilson's disease presenting with an unusual cough.
Topics: Adult; Chelating Agents; Cough; Hepatolenticular Degeneration; Humans; Magnetic Resonance Imaging; Male; Molybdenum; Putamen | 2005 |
[Corneal and encephalic abnormalities].
Topics: Adult; Brain; Chelating Agents; Cornea; Enzyme Inhibitors; Forecasting; Hepatolenticular Degeneration; Humans; Magnetic Resonance Imaging; Male; Molybdenum | 2006 |
Molybdenum. Monograph.
Topics: Animals; Coenzymes; Drug Hypersensitivity; Hepatolenticular Degeneration; Humans; Metalloproteins; Molybdenum; Molybdenum Cofactors; Neoplasms; Pteridines; Sulfites | 2006 |
Adverse reaction after tetrathiomolybdate treatment for Wilson's disease: a case report.
Topics: Adult; Copper; Dose-Response Relationship, Drug; Enzyme Inhibitors; Hepatolenticular Degeneration; Humans; Male; Molybdenum; Zinc | 2006 |
Treatment of the neurologic manifestations of Wilson's disease.
Topics: Dimercaprol; Hepatolenticular Degeneration; Humans; Molybdenum; Nervous System Diseases; Penicillamine | 1995 |
Treatment of Wilson's disease with ammonium tetrathiomolybdate. I. Initial therapy in 17 neurologically affected patients.
Topics: Adolescent; Adult; Copper; Female; Hepatolenticular Degeneration; Humans; Male; Molybdenum; Nervous System Diseases; Trichloroacetic Acid | 1994 |
Mechanisms of selective copper removal by tetrathiomolybdate from metallothionein in LEC rats.
Topics: Animals; Cadmium; Copper; Female; Hepatolenticular Degeneration; Injections, Intraperitoneal; Kidney; Liver; Male; Mass Spectrometry; Metallothionein; Metals; Molybdenum; Rats; Rats, Mutant Strains; Zinc | 1996 |
Systemic dispositions of molybdenum and copper after tetrathiomolybdate injection in LEC rats.
Topics: Animals; Brain; Chelating Agents; Copper; Disease Models, Animal; Feces; Gastric Mucosa; Half-Life; Hepatolenticular Degeneration; Injections, Intraperitoneal; Intestinal Mucosa; Intestines; Kidney; Liver; Lung; Male; Mass Spectrometry; Molybdenum; Rats; Rats, Mutant Strains; Rats, Wistar; Spleen; Stomach; Testis; Tissue Distribution | 1995 |
Molybdenum and copper kinetics after tetrathiomolybdate injection in LEC rats: specific role of serum albumin.
Topics: Animals; Chelating Agents; Chromatography, High Pressure Liquid; Copper; Disease Models, Animal; Dose-Response Relationship, Drug; Half-Life; Hepatolenticular Degeneration; Injections, Intraperitoneal; Liver; Male; Mass Spectrometry; Molybdenum; Protein Binding; Rats; Rats, Mutant Strains; Rats, Wistar; Serum Albumin; Tissue Distribution | 1995 |
Regression of Kayser-Fleischer rings during oral zinc therapy: correlation with systemic manifestations of Wilson's disease.
Topics: Administration, Oral; Adolescent; Adult; Brain Diseases; Copper; Cornea; Corneal Diseases; Female; Hepatolenticular Degeneration; Humans; Magnetic Resonance Imaging; Male; Molybdenum; Prospective Studies; Zinc | 1996 |
Depression in hepatolenticular degeneration (Wilson's disease).
Topics: Adult; Antidepressive Agents, Tricyclic; Chelating Agents; Comorbidity; Depressive Disorder; Drug Therapy, Combination; Follow-Up Studies; Hepatolenticular Degeneration; Humans; Male; Mianserin; Molybdenum; Psychomotor Disorders; Sleep Initiation and Maintenance Disorders | 1997 |
Cytopenias secondary to copper depletion complicating ammonium tetrathiomolybdate therapy for Wilson's disease.
Topics: Adult; Chelation Therapy; Copper; Female; Hepatolenticular Degeneration; Humans; Male; Molybdenum; Neutropenia; Thrombocytopenia | 1998 |
Targeting of tetrathiomolybdate on the copper accumulating in the liver of LEC rats.
Topics: Animals; Biological Transport, Active; Ceruloplasmin; Copper; Disease Models, Animal; Female; Hepatolenticular Degeneration; Liver; Metallothionein; Molybdenum; Protein Binding; Rats; Rats, Mutant Strains | 1998 |
The effect of subcutaneous tetrathiomolybdate administration on copper and iron metabolism, including their regional redistribution in the brain, in the Long-Evans Cinnamon rat, a bona fide animal model for Wilson's disease.
Topics: Animals; Brain; Ceruloplasmin; Copper; Disease Models, Animal; Enzyme-Linked Immunosorbent Assay; Ferritins; Hepatolenticular Degeneration; Injections, Subcutaneous; Iron; Kidney; Liver; Male; Metallothionein; Molybdenum; Rats; Rats, Inbred LEC | 1999 |
Therapeutic effects of tetrathiomolybdate on hepatic dysfunction occurring naturally in Long-Evans Cinnamon (LEC) rats: a bona fide animal model for Wilson's disease.
Topics: Animals; Bile; Body Weight; Chelating Agents; Copper; Disease Models, Animal; Hepatolenticular Degeneration; Jaundice; Liver; Male; Molybdenum; Rats; Rats, Inbred F344; Rats, Long-Evans; Tissue Distribution | 1999 |
Comparative mechanism and toxicity of tetra- and dithiomolybdates in the removal of copper.
Topics: Animals; Ceruloplasmin; Chelating Agents; Copper; Drug Stability; Hepatolenticular Degeneration; Humans; Liver; Molybdenum; Rats; Rats, Long-Evans | 1999 |
Metabolic fate of the insoluble copper/tetrathiomolybdate complex formed in the liver of LEC rats with excess tetrathiomolybdate.
Topics: Animals; Copper; Disease Models, Animal; Feces; Half-Life; Hepatolenticular Degeneration; Liver; Molybdenum; Rats; Rats, Long-Evans | 2000 |
Reduction of copper and metallothionein in toxic milk mice by tetrathiomolybdate, but not deferiprone.
Topics: Animals; Copper; Deferiprone; Disease Models, Animal; Hepatolenticular Degeneration; Metallothionein; Mice; Mice, Mutant Strains; Molybdenum; Phenotype; Pyridones | 2002 |
Kayser-Fleischer ring as the presenting sign of Wilson disease.
Topics: Adolescent; Biopsy; Ceruloplasmin; Copper; Corneal Diseases; Descemet Membrane; Drug Therapy, Combination; Female; Hepatolenticular Degeneration; Humans; Liver Function Tests; Molybdenum; Zinc Acetate | 2002 |
The interactions of penicillamine with copper in vivo and the effect on hepatic metallothionein levels and copper/zinc distribution: the implications for Wilson's disease and arthritis therapy.
Topics: Animals; Arthritis; Copper; Cytosol; Hepatolenticular Degeneration; Humans; Injections, Intramuscular; Liver; Male; Metallothionein; Methionine; Molybdenum; Organometallic Compounds; Penicillamine; Rats; Rats, Inbred Strains; Reference Values; Zinc | 1992 |
Thiomolybdates in the treatment of Wilson's disease.
Topics: Hepatolenticular Degeneration; Humans; Molybdenum | 1992 |
Initial therapy of patients with Wilson's disease with tetrathiomolybdate.
Topics: Adolescent; Adult; Ceruloplasmin; Copper; Female; Hepatolenticular Degeneration; Humans; Male; Molybdenum | 1991 |
A comparison of the effects of penicillamine, trientine, and trithiomolybdate on [35S]-labeled metallothionein in vitro; implications for Wilson's disease therapy.
Topics: Animals; Copper; Cytosol; Hepatolenticular Degeneration; Liver; Male; Metallothionein; Molybdenum; Penicillamine; Rats; Rats, Inbred Strains; Sulfur Radioisotopes; Trientine | 1991 |
Quantitation of Cu-containing metallothionein by a Cd-saturation method.
Topics: Animals; Cadmium; Cadmium Radioisotopes; Cells, Cultured; Chemistry Techniques, Analytical; Child; Child, Preschool; Chromatography, Gel; Copper; Cysteine; Ethanolamines; Fibroblasts; Glutathione; Hepatolenticular Degeneration; Humans; Male; Metallothionein; Molybdenum; Rats; Rats, Inbred Strains | 1990 |
Can Wilson's disease patients be decoppered?
Topics: Animals; Copper; Drug Evaluation, Preclinical; Hepatolenticular Degeneration; Liver; Molybdenum; Rats | 1989 |
Reversible pancytopenia secondary to treatment with tetrathiomolybdate.
Topics: Adult; Female; Hepatolenticular Degeneration; Humans; Male; Molybdenum; Pancytopenia | 1986 |
Essential micronutrient elements. Biochemistry and changes in liver disorders.
Topics: Alcohol Oxidoreductases; Cadmium; Copper; Hair; Hepatolenticular Degeneration; Humans; Iron; Liver Cirrhosis; Liver Diseases; Manganese; Molybdenum; Selenium; Trace Elements; Zinc | 1970 |
[Changes in the content of several microelements (copper, iron, zinc, manganese and molybdenum) in the blood and urine in hepato-cerebral dystrophy].
Topics: Adolescent; Adult; Copper; Female; Hepatolenticular Degeneration; Humans; Iron; Male; Manganese; Molybdenum; Trace Elements; Zinc | 1968 |